Please assess the completion status of the following clinical trial:

Trial Title: The Microvascular Function of GLP-1 and Its Analogues

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lean BMI ≤ 25.0 kg/m2~* Obese BMI ≥30.0kg/m2~* Non diabetic subjects and subjects with Type 2 diabetes on stable medication for at least 3 months~Exclusion Criteria:~* cardiovascular disease~* Raynaud's disease~* current treatment with any anti-hypertensive~* lipid lowering therapies~* severe hepatic impairment~* pregnancy and lactation~* subjects with Type 2 diabetes on insulin therapy~* subjects with Type 2 diabetes on sulphonylureas~* subjects with Type 2 diabetes on incretin based therapies~* subjects with Type 2 diabetes and peripheral vascular disease~* subjects with Type 2 diabetes and history of advanced retinopathy~* subjects with Type 2 diabetes and advanced nephropathy~* subjects with Type 2 diabetes with uncontrolled diabetes (HbA1c \> 8.5%)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DPP-IV inhibitor (Type: ACTIVE_COMPARATOR): Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
- Placebo pill (Type: PLACEBO_COMPARATOR): One placebo tablet before microinjection

Based on this trial design, predict the completion outcome and termination type (if applicable).